# Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

> **NCT06766591** · NA · NOT_YET_RECRUITING · sponsor: **Jiangsu Province Nanjing Brain Hospital** · enrollment: 36 (estimated)

## Conditions studied

- NSCLC
- Chemotherapy
- Leptomeningeal Metastases
- EGFR-TKI
- AK112

## Interventions

- **DRUG:** Ivonescimab combined with chemotherapy

## Key facts

- **NCT ID:** NCT06766591
- **Lead sponsor:** Jiangsu Province Nanjing Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-01-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06766591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06766591, "Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06766591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*